+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Graves Disease Market - Global Forecast 2026-2032- Product Image
Graves Disease Market - Global Forecast 2026-2032- Product Image
Sale

Graves Disease Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674290
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Graves Disease Market is projected to reach USD 2.61 Billion in 2026. It is expected to continue growing at a CAGR of 6.41%, reaching USD 3.80 Billion by 2032.

Graves disease is an autoimmune thyroid disorder in which thyroid-stimulating immunoglobulins activate the TSH receptor, leading to hyperthyroidism and, in many patients, extrathyroidal manifestations such as thyroid eye disease and dermopathy. It is the most common cause of hyperthyroidism in iodine-sufficient populations and disproportionately affects women, with onset frequently occurring in adulthood. The clinical burden extends beyond thyroid hormone excess, affecting cardiovascular risk, bone health, fertility, pregnancy outcomes, mental well-being, and quality of life. Diagnosis is increasingly anchored in sensitive thyroid function testing, TSH receptor antibody assays, thyroid ultrasound, and risk-based assessment of eye involvement. Treatment pathways typically include antithyroid drugs, radioactive iodine, thyroidectomy, beta-blockers for symptom control, and specialized therapies for moderate-to-severe thyroid eye disease. Current clinical priorities focus on earlier diagnosis, individualized treatment selection, long-term relapse monitoring, safer care during pregnancy, and integrated endocrinology-ophthalmology management.

Transformative Shifts in the Graves Disease Landscape

The Graves disease landscape is shifting from symptom-led management toward precision-oriented, multidisciplinary care. Clinical guidelines increasingly emphasize confirmation of autoimmune etiology with TSH receptor antibodies, evaluation for thyroid eye disease at diagnosis, smoking cessation support, and shared decision-making across antithyroid drugs, radioactive iodine, and surgery. The growing recognition of thyroid eye disease as a distinct inflammatory and fibrotic condition is changing care models by encouraging earlier referral to ophthalmology and stratification by disease activity and severity. Patient expectations are also evolving, with greater demand for therapies that reduce relapse, preserve quality of life, and minimize lifelong treatment burden. At the same time, health systems are expanding tele-endocrinology, remote lab review, and digital follow-up for chronic thyroid management, while specialist capacity constraints continue to shape access to timely diagnosis and advanced treatment.

Cumulative Impact of Artificial Intelligence on Graves Disease Care

Artificial intelligence is beginning to influence Graves disease care through decision support, imaging analysis, workflow optimization, and patient monitoring. In diagnostics, AI-enabled interpretation of thyroid ultrasound and orbital imaging can support identification of gland vascularity patterns, nodules requiring evaluation, and signs of thyroid eye disease, although clinical validation and physician oversight remain essential. Predictive analytics may help identify patients at higher risk of relapse after antithyroid drug withdrawal, adverse drug reactions, worsening ophthalmopathy, or treatment nonadherence by integrating laboratory trends, antibody levels, demographics, comorbidities, and care utilization patterns. Natural language processing can streamline extraction of thyroid-related symptoms, pregnancy status, smoking history, medication history, and eye findings from electronic health records. The cumulative impact of AI is likely to be strongest where it improves triage, shortens time to specialist review, supports guideline adherence, and enables proactive follow-up without replacing clinician judgment.

Key Regional Insights in Graves Disease

Asia-Pacific carries a substantial clinical workload due to its large population base, expanding endocrine testing infrastructure, and rising diagnosis of autoimmune thyroid disease in urban health systems. Japan, South Korea, Australia, China, and India show increasing integration of antibody testing, thyroid ultrasound, and specialized ophthalmology referral pathways, although access varies between metropolitan and rural settings. Europe benefits from established endocrine societies, structured referral pathways, and high use of evidence-based protocols, with continued emphasis on standardized management of orbitopathy, smoking-related risk, pregnancy-specific thyroid care, and antithyroid drug safety monitoring. North America demonstrates mature diagnostic availability, strong guideline adoption, and broad use of endocrinology-led care, with increasing attention to thyroid eye disease, patient-reported outcomes, and continuity of care for women of reproductive age. Latin America is characterized by improving laboratory access and specialist networks in major urban centers, while uneven insurance coverage and healthcare fragmentation can delay definitive treatment and long-term monitoring. Africa faces the greatest constraints in thyroid antibody testing, nuclear medicine availability, and specialist access, making clinical recognition, affordable thyroid function testing, and referral capacity central to improving Graves disease outcomes. The Middle East is advancing endocrine care through tertiary hospitals and specialty clinics, particularly in GCC health systems, while access remains variable across lower-resource settings and geographically dispersed populations.

Key Group Insights Across NATO, G7, BRICS, EU, ASEAN, and GCC

NATO member countries overlap significantly with high-income European and North American health systems, where resilient pharmaceutical supply chains, nuclear medicine capacity, and integrated specialist networks are important for maintaining continuity in thyroid disease care. G7 countries generally demonstrate high availability of thyroid function testing, specialist referral, advanced imaging, and multidisciplinary care, with policy emphasis on chronic disease quality metrics, pharmacovigilance, and patient-centered outcomes. BRICS countries collectively represent a diverse Graves disease environment, combining advanced tertiary capabilities in major cities with persistent access gaps in secondary and rural care; large patient volumes create opportunities for digital triage, standardized protocols, and workforce training. The European Union benefits from harmonized clinical practice influence, cross-border research collaboration, and established pharmacovigilance systems, supporting structured care for antithyroid drug safety, pregnancy-related thyroid disease, and orbitopathy. ASEAN countries are strengthening Graves disease diagnosis through expanding private and public laboratory networks, but access to endocrinologists, radioactive iodine facilities, and orbital specialists remains uneven across archipelagic and rural geographies. GCC health systems are investing in specialty endocrine clinics, digital health infrastructure, and tertiary care capacity, supporting more consistent diagnosis and management of Graves hyperthyroidism and thyroid eye disease.

Key Country Insights in Graves Disease

China is expanding thyroid disease detection through large hospital systems, growing laboratory availability, and increasing use of ultrasound and antibody testing, while access remains stronger in major cities than in lower-tier and rural settings. The United States has extensive access to thyroid function testing, endocrinology services, radioactive iodine, thyroid surgery, and specialized thyroid eye disease care, though insurance design and regional specialist shortages can affect timely treatment. Japan has deep clinical experience in Graves disease, including long-term antithyroid drug management and thyroid eye disease assessment, while India faces high patient volumes and variable access between urban specialists and rural primary care. Germany, France, Italy, and Spain have robust diagnostic infrastructure, established endocrine and nuclear medicine capabilities, and multidisciplinary capacity for complex thyroid and eye disease, although regional access and follow-up intensity can vary. The United Kingdom relies on structured primary care testing and specialist referral pathways, with national guidance supporting consistent management of hyperthyroidism and orbitopathy. Australia benefits from strong primary care referral systems and specialist networks, while South Korea combines advanced diagnostics, high healthcare utilization, and tertiary specialty care, supporting early identification and structured treatment for Graves hyperthyroidism and ophthalmic complications. Canada provides guideline-driven care through publicly funded systems, with referral wait times and geographic access influencing specialist evaluation. Russia maintains established endocrine and nuclear medicine services in major centers, with regional variability in access. Brazil and Mexico show strong endocrine expertise in major cities, while disparities in diagnostic access, treatment continuity, and specialist follow-up affect outcomes outside tertiary centers.

Actionable Recommendations for Graves Disease Industry Leaders

Industry leaders should prioritize solutions that shorten diagnostic delays, support individualized treatment decisions, and improve longitudinal monitoring. Practical actions include expanding access to reliable TSH receptor antibody testing, integrating ophthalmology screening into Graves disease pathways, building digital tools for laboratory trend tracking, and supporting clinician education on pregnancy, relapse risk, adverse drug reactions, and thyroid eye disease. Healthcare organizations should develop multidisciplinary referral protocols linking primary care, endocrinology, ophthalmology, nuclear medicine, and endocrine surgery. Technology developers should focus on clinically validated AI tools that enhance triage, imaging interpretation, adherence support, and risk stratification while meeting data privacy and regulatory expectations. Therapeutic innovators should align development priorities with unmet needs in durable remission, safer immunomodulation, eye disease control, and patient-reported quality-of-life improvement. Payers and policymakers can improve outcomes by supporting affordable diagnostic testing, timely specialist access, smoking cessation interventions, and standardized follow-up for high-risk groups.

Research Methodology

This executive summary is based on a structured synthesis of verified clinical and public health evidence from peer-reviewed medical literature, endocrine and ophthalmology guidelines, epidemiological publications, regulatory references, and healthcare system documentation. The methodology emphasizes triangulation across authoritative sources to assess disease burden, diagnostic standards, treatment pathways, regional access patterns, and technology-driven care developments. Evidence was evaluated for clinical relevance, recency, methodological quality, and applicability across regions and healthcare settings. The analysis excludes market sizing, revenue estimation, market share assessment, and forecasting, focusing instead on disease dynamics, care delivery, adoption factors, and actionable implications for stakeholders in Graves disease management.

Conclusion

Graves disease remains a high-impact autoimmune endocrine disorder requiring timely diagnosis, sustained monitoring, and coordinated care across thyroid and ophthalmic specialties. The field is moving toward more individualized, evidence-based management supported by antibody testing, imaging, multidisciplinary pathways, and digital health tools. Regional differences in laboratory access, specialist availability, nuclear medicine capacity, and healthcare financing continue to shape patient outcomes. Artificial intelligence and connected care models offer meaningful potential to improve triage, relapse prediction, and follow-up, but their value depends on clinical validation, equitable implementation, and integration into existing workflows. Stakeholders that focus on earlier detection, patient-centered treatment selection, thyroid eye disease readiness, and access-oriented care models will be best positioned to improve outcomes in Graves disease.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Graves Disease Market, by Diagnostics
7.1. Introduction
7.2. Blood Tests
7.2.1. Thyroid-stimulating Hormone (TSH) Levels
7.2.2. Free T4 & T3 Levels
7.2.3. TSH Receptor Antibodies (TSH-RAb)
7.3. Imaging Tests
7.3.1. Thyroid Ultrasound
7.3.2. Radioactive Iodine Uptake
7.4. Physical Examination
8. Graves Disease Market, by Treatment Type
8.1. Introduction
8.2. Antithyroid Medications
8.3. Radioactive Iodine Therapy
8.4. Surgical Interventions
9. Graves Disease Market, by Drug Class
9.1. Introduction
9.2. Thionamides
9.2.1. Methimazole
9.2.2. Propylthiouracil
9.2.3. Carbimazole
9.3. Beta Blockers
9.4. Corticosteroids
10. Graves Disease Market, by Route Of Administration
10.1. Introduction
10.2. Oral
10.3. Intravenous
11. Graves Disease Market, by Age Group
11.1. Introduction
11.2. Pediatric
11.3. Adult
11.4. Geriatric
12. Graves Disease Market, by Line Of Therapy
12.1. Introduction
12.2. First Line Therapy
12.3. Second Line Therapy
12.4. Third Line Therapy
13. Graves Disease Market, by End User
13.1. Introduction
13.2. Hospitals
13.3. Clinics
13.4. Ambulatory Surgical Centers
13.5. Diagnostic Laboratories
14. Graves Disease Market, by Distribution Channel
14.1. Introduction
14.2. Hospital Pharmacies
14.3. Retail Pharmacies
14.4. Online Pharmacies
15. Graves Disease Market, by Region
15.1. Asia-Pacific
15.2. Europe
15.3. North America
15.4. Latin America
15.5. Africa
15.6. Middle East
16. Graves Disease Market, by Group
16.1. NATO
16.2. G7
16.3. BRICS
16.4. European Union
16.5. ASEAN
16.6. GCC
17. Graves Disease Market, by Country
17.1. China
17.2. United States
17.3. Japan
17.4. India
17.5. Germany
17.6. United Kingdom
17.7. Australia
17.8. France
17.9. South Korea
17.10. Italy
17.11. Canada
17.12. Russia
17.13. Brazil
17.14. Mexico
17.15. Spain
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. FPNV Positioning Matrix, 2025
18.3. Market Concentration Analysis, 2025
18.3.1. Concentration Ratio (CR)
18.3.2. Herfindahl Hirschman Index (HHI)
18.4. Recent Developments & Impact Analysis, 2025
18.5. Product Portfolio Analysis, 2025
18.6. Benchmarking Analysis, 2025
19. Company Profiles
19.1. Abbott Laboratories
19.2. AdvanceCor GmbH
19.3. Amgen Inc.
19.4. Cadila Pharmaceuticals Limited
19.5. CORONA Remedies Limited
19.6. Daxia Healthcare Pvt Ltd.
19.7. Eris Lifesciences Ltd
19.8. F. Hoffmann-La Roche Ltd.
19.9. Immunovant, Inc. by Roivant Sciences Ltd.
19.10. Macleods Pharmaceuticals Ltd.
19.11. Merck KGaA
19.12. Novartis AG
19.13. Pfizer Inc.
19.14. Salvavidas Pharmaceutical Pvt. Ltd.
19.15. Siemens Healthineers AG
19.16. Steris Healthcare Pvt Ltd
19.17. Sun Pharmaceutical Industries Ltd
19.18. Synmedic Laboratories by Dhanuka Laboratories Limited
19.19. Teva Pharmaceutical Industries Ltd.
19.20. Thermo Fisher Scientific Inc.
19.21. Wellona Pharma
List of Figures
FIGURE 1. GLOBAL GRAVES DISEASE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL GRAVES DISEASE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL GRAVES DISEASE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL GRAVES DISEASE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL GRAVES DISEASE MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 15. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
FIGURE 17. GLOBAL GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 21. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL GRAVES DISEASE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 25. GLOBAL GRAVES DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL GRAVES DISEASE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29. GLOBAL GRAVES DISEASE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL GRAVES DISEASE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL GRAVES DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BLOOD TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BLOOD TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BLOOD TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL THYROID-STIMULATING HORMONE (TSH) LEVELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL THYROID-STIMULATING HORMONE (TSH) LEVELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL THYROID-STIMULATING HORMONE (TSH) LEVELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL FREE T4 & T3 LEVELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL FREE T4 & T3 LEVELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL FREE T4 & T3 LEVELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL TSH RECEPTOR ANTIBODIES (TSH-RAB) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL TSH RECEPTOR ANTIBODIES (TSH-RAB) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL TSH RECEPTOR ANTIBODIES (TSH-RAB) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL IMAGING TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL IMAGING TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL IMAGING TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL THYROID ULTRASOUND MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL THYROID ULTRASOUND MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL THYROID ULTRASOUND MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL RADIOACTIVE IODINE UPTAKE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL RADIOACTIVE IODINE UPTAKE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL RADIOACTIVE IODINE UPTAKE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PHYSICAL EXAMINATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PHYSICAL EXAMINATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PHYSICAL EXAMINATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ANTITHYROID MEDICATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ANTITHYROID MEDICATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ANTITHYROID MEDICATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL RADIOACTIVE IODINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL RADIOACTIVE IODINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL RADIOACTIVE IODINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL THIONAMIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL THIONAMIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL THIONAMIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL METHIMAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL METHIMAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL METHIMAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PROPYLTHIOURACIL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PROPYLTHIOURACIL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PROPYLTHIOURACIL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL CARBIMAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL CARBIMAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CARBIMAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL BETA BLOCKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL FIRST LINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL FIRST LINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL FIRST LINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL SECOND LINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SECOND LINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SECOND LINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL THIRD LINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL THIRD LINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL THIRD LINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 120. EUROPE GRAVES DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. EUROPE GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 122. EUROPE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 123. EUROPE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 124. EUROPE GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 125. EUROPE GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 126. EUROPE GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 127. EUROPE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 128. EUROPE GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 129. EUROPE GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 130. EUROPE GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. EUROPE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. AFRICA GRAVES DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 158. AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 159. AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 160. AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 161. AFRICA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 162. AFRICA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 163. AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 164. AFRICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 165. AFRICA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 166. AFRICA GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 167. AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 168. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL GRAVES DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 181. NATO GRAVES DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. NATO GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 183. NATO GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 184. NATO GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 185. NATO GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 186. NATO GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 187. NATO GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 188. NATO GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 189. NATO GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 190. NATO GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 191. NATO GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 192. NATO GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 193. G7 GRAVES DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 194. G7 GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 195. G7 GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 196. G7 GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 197. G7 GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 198. G7 GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 199. G7 GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 200. G7 GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 201. G7 GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 202. G7 GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 203. G7 GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. G7 GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. BRICS GRAVES DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 206. BRICS GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 207. BRICS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 208. BRICS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 209. BRICS GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 210. BRICS GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 211. BRICS GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 212. BRICS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 213. BRICS GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 214. BRICS GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 215. BRICS GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 216. BRICS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 229. ASEAN GRAVES DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 230. ASEAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 231. ASEAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 232. ASEAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 233. ASEAN GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 234. ASEAN GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 235. ASEAN GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 236. ASEAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 237. ASEAN GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 238. ASEAN GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 239. ASEAN GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 240. ASEAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 241. GCC GRAVES DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 242. GCC GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 243. GCC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 244. GCC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 245. GCC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 246. GCC GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 247. GCC GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 248. GCC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 249. GCC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 250. GCC GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 251. GCC GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. GCC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 253. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 254. CHINA GRAVES DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. CHINA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 256. CHINA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 257. CHINA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 258. CHINA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 259. CHINA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 260. CHINA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 261. CHINA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 262. CHINA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 263. CHINA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 264. CHINA GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 265. CHINA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 266. UNITED STATES GRAVES DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 267. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 268. UNITED STATES GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 269. UNITED STATES GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 270. UNITED STATES GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 271. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 272. UNITED STATES GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 273. UNITED STATES GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 274. UNITED STATES GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 275. UNITED STATES GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 278. JAPAN GRAVES DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. JAPAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 280. JAPAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 281. JAPAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 282. JAPAN GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 283. JAPAN GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 284. JAPAN GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 285. JAPAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 286. JAPAN GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 287. JAPAN GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 288. JAPAN GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. JAPAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 290. INDIA GRAVES DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. INDIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 292. INDIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 293. INDIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 294. INDIA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 295. INDIA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 296. INDIA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 297. INDIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 298. INDIA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 299. INDIA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 300. INDIA GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 301. INDIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 302. GERMANY GRAVES DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. GERMANY GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 304. GERMANY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 305. GERMANY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 306. GERMANY GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 307. GERMANY GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 308. GERMANY GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 309. GERMANY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 310. GERMANY GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 311. GERMANY GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 312. GERMANY GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. GERMANY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 314. UNITED KINGDOM GRAVES DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 315. UNITED KINGDOM GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 316. UNITED KINGDOM GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 317. UNITED KINGDOM GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 318. UNITED KINGDOM GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 319. UNITED KINGDOM GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 320. UNITED KINGDOM GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 321. UNITED KINGDOM GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 322. UNITED KINGDOM GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 323. UNITED KINGDOM GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 324. UNITED KINGDOM GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 325. UNITED KINGDOM GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 326. AUSTRALIA GRAVES DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 328. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 329. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 330. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 331. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 332. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 333. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 334. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 335. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 336. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 337. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 338. FRANCE GRAVES DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 339. FRANCE GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 340. FRANCE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 341. FRANCE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 342. FRANCE GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 343. FRANCE GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 344. FRANCE GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 345. FRANCE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 346. FRANCE GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 347. FRANCE GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 348. FRANCE GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 349. FRANCE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 350. SOUTH KOREA GRAVES DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 351. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 352. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 353. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 354. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 355. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 356. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 357. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 358. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 359. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 360. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 361. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 362. ITALY GRAVES DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 363. ITALY GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 364. ITALY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032 (USD MILLION)
TABLE 365. ITALY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 366. ITALY GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 367. ITALY GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 368. ITALY GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2017-2032 (USD MILLION)
TABLE 369. ITALY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 370. ITALY GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 371. ITALY GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 372. ITALY GRAVES DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 373. ITALY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 374. CANADA GRAVES DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 375. CANADA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 376. CANADA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2017-2032

Companies Mentioned

  • Abbott Laboratories
  • AdvanceCor GmbH
  • Amgen Inc.
  • Cadila Pharmaceuticals Limited
  • CORONA Remedies Limited
  • Daxia Healthcare Pvt Ltd.
  • Eris Lifesciences Ltd
  • F. Hoffmann-La Roche Ltd.
  • Immunovant, Inc. by Roivant Sciences Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Siemens Healthineers AG
  • Steris Healthcare Pvt Ltd
  • Sun Pharmaceutical Industries Ltd
  • Synmedic Laboratories by Dhanuka Laboratories Limited
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Wellona Pharma

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.61 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.8 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Graves' Disease (Overactive Thyroid) Market - Global Strategic Business Report - Product Image

Graves' Disease (Overactive Thyroid) Market - Global Strategic Business Report

  • Report
  • 386 Pages
  • Global
From
Carbimazole Market - Global Forecast 2026-2032 - Product Image

Carbimazole Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Graves Disease Market Outlook 2026-2034: Market Share, and Growth Analysis by Treatment (Anti-Thyroid Medication, Radioactive Iodine Therapy, Surgery (Thyroidectomy), Targeted Immunotherapies & Biologics, Ultrasound-Guided Thermal Ablation), Patient Age Group, End-User - Product Image

Graves Disease Market Outlook 2026-2034: Market Share, and Growth Analysis by Treatment (Anti-Thyroid Medication, Radioactive Iodine Therapy, Surgery (Thyroidectomy), Targeted Immunotherapies & Biologics, Ultrasound-Guided Thermal Ablation), Patient Age Group, End-User

  • Report
  • 160 Pages
  • Global
From
Goitre Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035 - Product Image

Goitre Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Regulatory T cells and Autoimmune Diseases - Product Image

Regulatory T cells and Autoimmune Diseases

  • Book

About the Graves Disease Market

Graves Disease is a type of autoimmune disorder that affects the thyroid gland. It is the most common cause of hyperthyroidism, a condition in which the thyroid produces too much of the hormone thyroxine. Symptoms of Graves Disease include weight loss, increased appetite, rapid heart rate, and bulging eyes. Treatment typically involves medications to reduce the production of thyroxine, as well as radioactive iodine therapy to destroy the thyroid gland. Allergy and Immunology is a medical specialty that focuses on the diagnosis and treatment of allergies and immune system disorders. Allergy and Immunology specialists are trained to diagnose and treat Graves Disease, as well as other autoimmune disorders. They may also provide advice on lifestyle changes to help manage the condition. Companies in the Graves Disease market include AbbVie, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.